Compare · AVTR vs SEER
AVTR vs SEER
Side-by-side comparison of Avantor Inc. (AVTR) and Seer Inc. (SEER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and SEER operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $10.62B, about 92.2x SEER ($115.2M).
- AVTR has been more active in the news (6 items in the past 4 weeks vs 3 for SEER).
- AVTR has more recent analyst coverage (25 ratings vs 8 for SEER).
- Company
- Avantor Inc.
- Seer Inc.
- Price
- $16.41+1.96%
- $2.03-0.73%
- Market cap
- $10.62B
- $115.2M
- 1M return
- -
- +6.01%
- 1Y return
- -
- -7.52%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 6
- 3
- Recent ratings
- 25
- 8
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Seer Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Discovery Life Sciences, LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Latest AVTR
- Avantor® to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026
- EVP and CFO Garner Todd W was granted 49,688 shares (SEC Form 4)
- SEC Form 3 filed by new insider Garner Todd W
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Avantor appoints new Chief Financial Officer
- UBS initiated coverage on Avantor with a new price target
- Amendment: Avantor Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- President and CEO Ligner Emmanuel covered exercise/tax liability with 29,803 shares, decreasing direct ownership by 4% to 737,334 units (SEC Form 4) to satisfy withholding obligation
- EVP, Chief HR Officer Hankamer Brittany covered exercise/tax liability with 181 shares, decreasing direct ownership by 0.07% to 248,864 units (SEC Form 4) (withholding tax)
Latest SEER
- SEC Form 3 filed by Seer Inc.
- Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
- Seer Announces CFO Transition
- SEC Form 8-K filed by Seer Inc.
- Seer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale
- Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.’s Board of Directors
- PRESIDENT & CFO Horn David R. sold $14,809 worth of shares (7,309 units at $2.03), decreasing direct ownership by 1% to 486,650 units (SEC Form 4) to cover taxes
- Radoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers
- SEC Form 10-Q filed by Seer Inc.
- Seer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits